Reyes Arranz
About
Reyes Arranz is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics.
According to data from OpenAlex, Reyes Arranz has authored 36 papers receiving a total of 757 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Pathology and Forensic Medicine, 23 papers in Oncology and 11 papers in Genetics. Recurrent topics in Reyes Arranz's work include Lymphoma Diagnosis and Treatment (25 papers), Chronic Lymphocytic Leukemia Research (10 papers) and Viral-associated cancers and disorders (10 papers). Reyes Arranz is often cited by papers focused on Lymphoma Diagnosis and Treatment (25 papers), Chronic Lymphocytic Leukemia Research (10 papers) and Viral-associated cancers and disorders (10 papers). Reyes Arranz collaborates with scholars based in Spain, United States and Italy. Reyes Arranz's co-authors include Eulogio Conde, Marı́a Dolores Caballero, Anna Sureda, José Rodríguez, Ángel León, Antonio Gutiérrez, Carmen Albó, Josep‐María Ribera, Maurizio Bendandi and Julián Marín and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.
In The Last Decade
Reyes Arranz
36 papers receiving 739 citations
Peers
Reyes Arranz
Liuyan Jiang United States
Ni‐Chun Tsai United States
T. Al Saati France
Rie Hyo Japan
Thamathorn Assanasen Thailand
Jean‐Marc Schiano de Colella France
J. M. Castrillo Spain
Anne Y. Matsushima United States
Pierre Brousset France
Bruce G. Raphael United States
Citations per year, relative to Reyes Arranz Reyes Arranz (= 1×)
peers
Liuyan Jiang
Countries citing papers authored by Reyes Arranz
Since
Specialization
Citations
This map shows the geographic impact of Reyes Arranz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Reyes Arranz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Reyes Arranz more than expected).
Fields of papers citing papers by Reyes Arranz
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Reyes Arranz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Reyes Arranz. The network helps show where Reyes Arranz may publish in the future.
Co-authorship network of co-authors of Reyes Arranz
This figure shows the co-authorship network connecting the top 25 collaborators of Reyes Arranz. A scholar is included among the top collaborators of Reyes Arranz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Reyes Arranz. Reyes Arranz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Rogado, Jacobo, Nuria Romero-Laorden, J.M. Sanchez Torres, et al.. (2019). Association of efficacy of anti-PD-1 immunotherapy in patients with advanced cancer with immune-related adverse events (irAEs).. Journal of Clinical Oncology. 37(15_suppl). e14064–e14064.
2.
Gascón, Pere, Reyes Arranz, Joan Bargay, & Fernando Ramos. (2017). Fatigue- and health-related quality-of-life in anemic patients with lymphoma or multiple myeloma. Supportive Care in Cancer. 26(4). 1253–1264.
3.
León, Nieves Gómez, Roberto C. Delgado Bolton, Reyes Arranz, et al.. (2017). Multicenter Comparison of Contrast-Enhanced FDG PET/CT and 64-Slice Multi–Detector-Row CT for Initial Staging and Response Evaluation at the End of Treatment in Patients With Lymphoma. Clinical Nuclear Medicine. 42(8). 595–602.
4.
Cabrero, Mónica, Alejandro Martı́n, Javier Briones, et al.. (2016). Phase II Study of Yttrium-90-Ibritumomab Tiuxetan as Part of Reduced-Intensity Conditioning (with Melphalan, Fludarabine ± Thiotepa) for Allogeneic Transplantation in Relapsed or Refractory Aggressive B Cell Lymphoma: A GELTAMO Trial. Biology of Blood and Marrow Transplantation. 23(1). 53–59.
5.
Martı́n, Alejandro, Alba Redondo, David Valcárcel, et al.. (2014). A Phase 2 Study from Spanish Geltamo Group Investigating the Efficacy and Safety of Bendamustine As Part of Conditioning Regimen for Autologous Stem-Cell Transplantation in Patients with Aggressive Lymphomas: Second Interim Analysis. Blood. 124(21). 2524–2524.
6.
Duarte, Rafael F., Ariane Boumendil, Francesco Onida, et al.. (2013). Allogeneic Hematopoietic Cell Transplantation For Patients With Mycosis Fungoides and Sezary Syndrome: The Experience Of The EBMT Lymphoma Working Party With An Extended Five-Year Follow Up. Blood. 122(21). 2094–2094.
7.
Duarte, Rafael F., Carmen Canals, Francesco Onida, et al.. (2010). Allogeneic Hematopoietic Cell Transplantation for Patients With Mycosis Fungoides and Sézary Syndrome: A Retrospective Analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Journal of Clinical Oncology. 28(29). 4492–4499.
8.
Sáez, Ana I., Mónica García‐Cosío, Antonio José Sáez-Castillo, et al.. (2009). Identification of biological markers of sensitivity to high-clinical-risk-adapted therapy for patients with diffuse large B-cell lymphoma. Leukemia & lymphoma. 50(4). 571–581.
9.
Robledo, Cristina, Juan Luis Garcı́a, Dolores Caballero, et al.. (2009). Array comparative genomic hybridization identifies genetic regions associated with outcome in aggressive diffuse large B‐cell lymphomas. Cancer. 115(16). 3728–3737.
10.
Sancho, Juan‐Manuel, Mireia Morgades, Reyes Arranz, et al.. (2008). Practice of central nervous system prophylaxis and treatment in acute leukemias in Spain. Prospective registry study. Medicina Clínica. 131(11). 401–405.
11.
Rodríguez, José, Eulogio Conde, Antonio Gutiérrez, et al.. (2007). Prolonged survival of patients with angioimmunoblastic T‐cell lymphoma after high‐dose chemotherapy and autologous stem cell transplantation. The GELTAMO experience. European Journal Of Haematology. 78(4). 290–296.
12.
Arranz, Reyes, Eulogio Conde, Carlos Grande, et al.. (2007). Dose‐escalated CHOP and tailored intensification with IFE according to early response and followed by BEAM/autologous stem‐cell transplantation in poor‐risk aggressive B‐cell lymphoma: a prospective study from the GEL–TAMO Study Group. European Journal Of Haematology. 80(3). 227–235.
13.
Rodríguez, José, Eulogio Conde, Antonio Gutiérrez, et al.. (2007). Frontline autologous stem cell transplantation in high‐risk peripheral T‐cell lymphoma: a prospective study from The Gel‐Tamo Study Group. European Journal Of Haematology. 79(1). 32–38.
14.
Alvarez, Iván, Anna Sureda, Marı́a Dolores Caballero, et al.. (2006). Nonmyeloablative Stem Cell Transplantation Is an Effective Therapy for Refractory or Relapsed Hodgkin Lymphoma: Results of a Spanish Prospective Cooperative Protocol. Biology of Blood and Marrow Transplantation. 12(2). 172–183.
15.
Rodríguez, José A., Marı́a Dolores Caballero, Antonio Gutiérrez, et al.. (2005). Prolonged Survival in Patients with Angioimmunoblastic T-Cell Lymphoma (AIL) after High-Dose Chemotherapy and Autologous Stem Cell Transplantation (ASCT). The GELTAMO Experience.. Blood. 106(11). 2082–2082.
16.
Gisbert, Javier P., Luisa Garcı́a-Buey, Reyes Arranz, et al.. (2004). The prevalence of hepatitis C virus infection in patients with non-Hodgkin's lymphoma. European Journal of Gastroenterology & Hepatology. 16(2). 135–138.
17.
Rodríguez, José, Marı́a Dolores Caballero, Antonio Gutiérrez, et al.. (2003). High dose chemotherapy and autologous stem cell transplantation in patients with peripheral T-cell lymphoma not achieving complete response after induction chemotherapy. The GEL-TAMO experience.. PubMed. 88(12). 1372–7.
18.
Cámara, Rafael de la, Arancha Alonso, Juan Luis Steegmann, et al.. (2002). Allogeneic hematopoietic stem cell transplantation in patients 50 years of age and older. PubMed. 87(9). 965–72.
19.
Arranz, Reyes, et al.. (2000). Trasplante de células progenitoras hematopoyéticas como tratamiento de rescate en pacientes con linfomas no hodgkinianos agresivos. Medicina Clínica. 114(4). 128–131.
20.
Peñarrubia, María Jesús, Juan Luis Steegmann, Esperanza Lavilla, et al.. (1995). Hypertriglyceridemia may be severe in CML patients treated with interferon‐α. American Journal of Hematology. 49(3). 240–241.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Liuyan Jiang Breakdown of academic impact, for papers by Ni‐Chun Tsai Breakdown of academic impact, for papers by T. Al Saati Breakdown of academic impact, for papers by Rie Hyo Breakdown of academic impact, for papers by Thamathorn Assanasen Breakdown of academic impact, for papers by Jean‐Marc Schiano de Colella Breakdown of academic impact, for papers by J. M. Castrillo Breakdown of academic impact, for papers by Anne Y. Matsushima Breakdown of academic impact, for papers by Pierre Brousset Breakdown of academic impact, for papers by Bruce G. Raphael